Related Experiment Video

Updated: Jul 26, 2025

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.3K

Correlation between Apolipoprotein A1 and the Occurrence and Prognosis of Cardiovascular Events in Peritoneal

Yu-Di Zhou, Jun-Jie Zhu, Hang-Yan Zhang

    Clinical Laboratory
    |June 12, 2023
    PubMed

    Insights

    Low levels of apolipoprotein A1 (ApoA1) in peritoneal dialysis patients indicate a higher risk of cardiovascular events and mortality. ApoA1 is a significant predictor of adverse outcomes in this population.

    Area of Science:

    • Nephrology
    • Cardiology
    • Biochemistry

    Background:

    • Cardiovascular disease is a leading cause of mortality in patients undergoing peritoneal dialysis (PD).
    • Apolipoprotein A1 (ApoA1) plays a crucial role in reverse cholesterol transport and has potential as a biomarker for cardiovascular risk.

    Purpose of the Study:

    • To investigate the association between apolipoprotein A1 levels and the occurrence of cardiovascular events in patients on peritoneal dialysis.
    • To evaluate the prognostic value of apolipoprotein A1 in predicting cardiovascular outcomes and all-cause mortality in this patient cohort.

    Main Methods:

    • Retrospective analysis of 80 end-stage renal disease patients on peritoneal dialysis.
    • Patients were categorized into High Apolipoprotein A1 (H-ApoA1) and Low Apolipoprotein A1 (L-ApoA1) groups based on the median ApoA1 value (> 1.145g/L vs. < 1.145g/L).
    • Clinical data, including cardiovascular events and mortality rates, were compared between the two groups.

    Main Results:

    • The L-ApoA1 group exhibited higher BMI, hemoglobin, glycated hemoglobin, HOMA-IR, and HDL levels, but lower total Kt/V, Ccr, triglycerides, total cholesterol, LDL, and CRP compared to the H-ApoA1 group.
    • Significantly higher rates of all-cause mortality, cardiovascular death, and cardiovascular events were observed in the L-ApoA1 group.
    • Apolipoprotein A1 was identified as a significant risk factor for all-cause mortality and cardiovascular events.

    Conclusions:

    • Reduced apolipoprotein A1 levels are associated with a poorer prognosis in peritoneal dialysis patients.
    • Low apolipoprotein A1 is a valuable predictive marker for increased cardiovascular event occurrence and mortality in this population.
    • Monitoring apolipoprotein A1 may aid in risk stratification and management of cardiovascular complications in peritoneal dialysis patients.
    Abstract

    More Related Videos

    Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure05:15

    Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

    Published on: June 10, 2025

    142
    Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis07:11

    Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis

    Published on: July 19, 2018

    15.4K

    Related Concept Videos

    Coronary Artery Disease I: Introduction01:30

    Coronary Artery Disease I: Introduction

    Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
    33
    Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications01:25

    Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications

    Peritoneal dialysis (PD) is a medical process that removes waste products and excess fluid from the body using the peritoneal membrane as a natural filter.Peritoneal Dialysis MethodsSeveral methods can be used for peritoneal dialysis, including Acute Intermittent Peritoneal Dialysis, Continuous Ambulatory Peritoneal Dialysis, and Automated Peritoneal Dialysis, also known as Continuous Cyclic Peritoneal Dialysis.Acute Intermittent Peritoneal Dialysis (AIPD) is used for patients with uremic...
    46
    Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

    Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

    Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
    These markers indicate stress or strain on the heart muscle:
    Natriuretic Peptides (BNP)
    Cardiac myocytes produce these hormones in response to ventricular stretching...
    127
    Chronic Kidney Disease II: Clinical Manifestations01:24

    Chronic Kidney Disease II: Clinical Manifestations

    Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
    42
    Hemodialysis I: Introduction01:25

    Hemodialysis I: Introduction

    Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
    69
    Peripheral Artery Disease I: Introduction01:30

    Peripheral Artery Disease I: Introduction

    Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs but also impacts other areas, such as the arms, thereby impairing overall circulation and organ function.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty deposits inside the arterial...
    11